Regulators Called for Alternatives to Animal Testing
The MHRA and international partners adopted a joint statement to replace animal testing in medicine development.
Updated on Oct. 5, 2026 in Veterinary Medicine
Live Poll
Should regulatory authorities prioritize non-animal testing methods for the development of new human medicines?
The UK Medicines and Healthcare products Regulatory Agency (MHRA) joined the International Coalition of Medicines Regulatory Authorities (ICMRA) in a global push to move away from animal testing. This initiative aims to transition medicine development from initial screening through post-authorisation activities toward non-animal methods.
Why it matters
Reducing reliance on animal models aims to improve the efficiency and ethical standards of drug development. Regulators are now clarifying how they assess non-animal data to increase developer confidence in replacing legacy testing practices.
Regulatory bodies now only permit animal testing for batch release when no equivalent non-animal method is available. Agencies are actively validating technologies including organ-on-a-chip, AI-driven predictive models, and 3D bioprinted tissues.
The players
Medicines and Healthcare products Regulatory Agency
The MHRA is the executive agency of the UK Department of Health and Social Care responsible for ensuring that medicines and medical devices meet standards of safety, quality, and efficacy.
International Coalition of Medicines Regulatory Authorities
The ICMRA is a global voluntary organization of medicine regulatory authorities that provides strategic leadership and coordination on high-level regulatory issues.
The details
The MHRA, an executive agency of the UK Department of Health and Social Care, is leading the move toward New Approach Methodologies. By reviewing non-animal data more rigorously, regulators aim to facilitate the phasing out of animal models that were previously standard in medicine research.
Timeline
In March 2026, the MHRA announced its commitment to phase out animal testing in medicine development.
On October 5, 2026, the ICMRA published a joint statement formalizing the global goal of replacing animal testing.
Culture Shift
The transition reflects a broader scientific movement toward synthetic biology and ethical research standards that prioritize predictive modeling over traditional animal-based diagnostics. This strategy aligns global regulatory frameworks with advancements in biotechnology, potentially setting a new standard for international drug approvals.
The shift toward non-animal testing may accelerate the drug development process, potentially bringing new treatments to market more efficiently. Patients and pet owners can expect future medications to be vetted through more advanced, data-driven predictive techniques.
The takeaway
This global collaboration signifies that the regulatory landscape is shifting to prioritize advanced computational and synthetic testing methods. Stakeholders should anticipate a regulatory environment that increasingly favors non-animal data for all stages of medicine authorization.
Further reading
For more information on the evolving standards for medicine testing, visit our Veterinary Medicine section.
More information
To review the full joint statement and coalition goals, visit the ICMRA official website.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Should regulatory authorities prioritize non-animal testing methods for the development of new human medicines?
